# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-134813
Filing Date
2026-03-31
Accepted
2026-03-31 16:49:08
Documents
70
Period of Report
2025-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-K | inkt-20251231.htm iXBRL | 10-K | 2366983
2 | EX-21.1 | inkt-ex21_1.htm | EX-21.1 | 6989
3 | EX-23.1 | inkt-ex23_1.htm | EX-23.1 | 3866
4 | EX-31.1 | inkt-ex31_1.htm | EX-31.1 | 17298
5 | EX-31.2 | inkt-ex31_2.htm | EX-31.2 | 17240
6 | EX-32.1 | inkt-ex32_1.htm | EX-32.1 | 10201
7 | EX-32.2 | inkt-ex32_2.htm | EX-32.2 | 10140
8 | GRAPHIC | img193888466_0.jpg | GRAPHIC | 129242
| Complete submission text file | 0001193125-26-134813.txt |  | 8312250

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
9 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | inkt-20251231.xsd | EX-101.SCH | 1169381
74 | EXTRACTED XBRL INSTANCE DOCUMENT | inkt-20251231_htm.xml | XML | 1023210

Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40908 | Film No.: 26822944
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)